Connecticut 2021 2021 Regular Session

Connecticut House Bill HB06387 Comm Sub / Analysis

Filed 05/08/2021

                     
Researcher: AR 	Page 1 	5/8/21 
 
 
 
OLR Bill Analysis 
HB 6387 (as amended by House "A")*  
 
AN ACT CONCERNING INSURANCE DISCRIMINATION AGAINST 
LIVING ORGAN DONORS.  
 
SUMMARY 
This bill prohibits an insurer issuing, delivering, or amending a life, 
long-term care, or disability-income protection insurance policy from 
discriminating against living organ donation by: 
1. declining or limiting coverage solely because the insured is a 
living organ donor,  
2. prohibiting the insured from donating an organ as a condition 
of maintaining coverage, or 
3. otherwise discriminating in offering, delivering, issuing, 
amending, or cancelling a policy by setting prices, conditions, or 
coverage of the policy solely because the insured is a living 
organ donor. 
The bill makes a violation of its provisions a Connecticut Unfair 
Insurance Practices Act (CUIPA) violation (see BACKGROUND).  
The bill also establishes a chronic kidney disease advisory 
committee to, among other things, work with policymakers, public 
health organizations and educational institutions to increase 
awareness of chronic kidney disease and develop related educational 
programs. Beginning by January 1, 2022, the committee must annually 
report its findings and recommendations to the Public Health 
Committee.  
*House Amendment “A” establishes the chronic kidney disease 
advisory committee.  
EFFECTIVE DATE: January 1, 2022, except the chronic kidney  2021HB-06387-R01-BA.DOCX 
 
Researcher: AR 	Page 2 	5/8/21 
 
disease advisory committee is effective upon passage.  
CHRONIC KIDNEY DISEA SE ADVISORY COMMITTE E 
Purposes 
Under the bill, the advisory committee must: 
1. work with policy makers, public health organizations, and 
educational institutions to (a) increase awareness of the disease 
in Connecticut and (b) develop educational programs that 
reduce the burden of kidney disease, include ongoing health 
and wellness campaigns based on relevant research, promote 
preventive screenings, and are promoted through social media 
and public relations campaigns; 
2. examine chronic kidney disease, kidney transplantation 
(including transplantation as a preferred treatment), living and 
deceased kidney donation, and racial disparities in the rates of 
afflicted individuals; 
3. examine methods to reduce the occurrence of chronic kidney 
disease by controlling the most common risk factors (i.e., 
diabetes and hypertension) through early detection and 
prevention at the community level and primary care disease 
management; 
4. identify barriers to adopting best practices and the policies 
available to address them; 
5. develop an equitable, sustainable, cost-effective plan to raise 
awareness about the importance of early detection, screening, 
diagnosis, and treatment of chronic kidney disease and 
prevention; and 
6. examine the potential for an opt-out organ or kidney donor 
registry.  
Membership 
Under the bill, the advisory committee consists of at least 21  2021HB-06387-R01-BA.DOCX 
 
Researcher: AR 	Page 3 	5/8/21 
 
required members and includes the chairs and ranking members of the 
Public Health Committee and the public health commissioner, or their 
designees. The remaining required members are appointed as follows:  
1. one appointed by the House speaker who represents the renal 
provider community; 
2. one by the Senate president pro tempore who represents a 
medical center with a kidney-related program; 
3. one each appointed by the House and Senate majority leaders; 
4. one each appointed by the House and Senate minority leaders; 
5. one appointed by the governor; 
6. one each appointed by the chief executive officers of the 
National Kidney Foundation and the American Kidney Fund;  
7. one each appointed by the chairs and ranking members of the 
Public Health Committee; and 
8. three appointed jointly by Public Health Committee chairs, one 
who represents the kidney physician community, one who 
represents a nonprofit organ procurement organization, and 
one who represents the Connecticut kidney patient community. 
In addition to the members described above, the Public Health 
Committee chairs may also appoint other members they deem 
necessary to represent public health clinics, community health centers 
minority health organizations, and health insurers.   
Under the bill, any of the legislatively appointed members may be 
General Assembly members. The appointing authorities must make 
initial appointments by 30 days after the bill’s passage and fill any 
vacancies.  
Under the bill, the House speaker and Senate president pro tempore 
select the advisory committee’s chairpersons from among the 
members. The chairpersons must schedule the first meeting and hold it  2021HB-06387-R01-BA.DOCX 
 
Researcher: AR 	Page 4 	5/8/21 
 
by 60 days after the bill’s passage.  
Administration 
The Office of Legislative Management, in consultation with the 
advisory committee’s chairpersons, must select committee’s 
administrative staff.  
The bill allows the advisory committee to conduct virtual meetings, 
at the chairpersons’ discretion.  
BACKGROUND 
Connecticut Unfair Insurance Practices Act 
CUIPA prohibits engaging in unfair or deceptive acts or practices in 
the business of insurance. It authorizes the insurance commissioner to 
conduct investigations and hearings, issue cease and desist orders, 
impose fines, revoke or suspend licenses, and order restitution for per 
se violations (i.e., violations specifically listed in statute). The law also 
allows the commissioner to ask the attorney general to seek injunctive 
relief in Superior Court if he believes someone is engaging in other 
unfair or deceptive acts not specifically defined in statute.  
Fines may be up to (1) $5,000 per violation to a $50,000 maximum or 
(2) $25,000 per violation to a $250,000 maximum in any six-month 
period if the violation was knowingly committed. The law also 
imposes a fine of up to $50,000, in addition to or in place of a license 
suspension or revocation, for violating a cease and desist order (CGS § 
38a-815 et seq.). 
COMMITTEE ACTION 
Insurance and Real Estate Committee 
Joint Favorable 
Yea 18 Nay 0 (03/11/2021)